7NWK
Crystal structure of CDK9-Cyclin T1 bound by compound 6
7NWK の概要
| エントリーDOI | 10.2210/pdb7nwk/pdb |
| 分子名称 | Cyclin-dependent kinase 9, Cyclin-T1, N-((1R,3R)-3-(7-(4-fluoro-2-methoxyphenyl)-3H-imidazo[4,5-b]pyridin-2-yl)cyclopentyl)acetamide (3 entities in total) |
| 機能のキーワード | inhibitor, kinase, transferase |
| 由来する生物種 | Homo sapiens (Human) 詳細 |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 68364.78 |
| 構造登録者 | |
| 主引用文献 | Barlaam, B.,De Savi, C.,Dishington, A.,Drew, L.,Ferguson, A.D.,Ferguson, D.,Gu, C.,Hande, S.,Hassall, L.,Hawkins, J.,Hird, A.W.,Holmes, J.,Lamb, M.L.,Lister, A.S.,McGuire, T.M.,Moore, J.E.,O'Connell, N.,Patel, A.,Pike, K.G.,Sarkar, U.,Shao, W.,Stead, D.,Varnes, J.G.,Vasbinder, M.M.,Wang, L.,Wu, L.,Xue, L.,Yang, B.,Yao, T. Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement. J.Med.Chem., 64:15189-15213, 2021 Cited by PubMed Abstract: Optimization of a series of azabenzimidazoles identified from screening hit and the information gained from a co-crystal structure of the azabenzimidazole-based lead bound to CDK9 led to the discovery of azaindoles as highly potent and selective CDK9 inhibitors. With the goal of discovering a highly selective and potent CDK9 inhibitor administrated intravenously that would enable transient target engagement of CDK9 for the treatment of hematological malignancies, further optimization focusing on physicochemical and pharmacokinetic properties led to azaindoles and . These compounds are highly potent and selective CDK9 inhibitors having short half-lives in rodents, suitable physical properties for intravenous administration, and the potential to achieve profound but transient inhibition of CDK9 . PubMed: 34647738DOI: 10.1021/acs.jmedchem.1c01249 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.81 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






